# A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)

> **NCT01276847** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 40 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Ustekinumab
- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT01276847
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276847, "A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01276847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*